Industry
Biotechnology
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:39 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 4:02 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 3:42 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 2:20 pm
Portfolio Pulse from Benzinga Insights
July 31, 2024 | 2:00 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:44 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 11:20 am
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 11:19 am
Portfolio Pulse from Avi Kapoor
July 16, 2024 | 5:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.